AR083770A1 - Metodos y composiciones, kit - Google Patents
Metodos y composiciones, kitInfo
- Publication number
- AR083770A1 AR083770A1 ARP110104129A ARP110104129A AR083770A1 AR 083770 A1 AR083770 A1 AR 083770A1 AR P110104129 A ARP110104129 A AR P110104129A AR P110104129 A ARP110104129 A AR P110104129A AR 083770 A1 AR083770 A1 AR 083770A1
- Authority
- AR
- Argentina
- Prior art keywords
- compositions
- methods
- peg
- treatment
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Métodos de tratamiento y para tratamiento, para mejorar o prevenir el cáncer colorrectal (CCR) en seres humanos utilizando polietilenglicol (PEG) o un copolímero de bloque de PEG tal como Pluronic® F68. Composiciones para utilizar en el tratamiento, mejoramiento y/o prevención de CCR que comprenden PEG. Dichas composiciones se pueden utilizar en los métodos de la presente.Reivindicación 37: La composición de cualquiera de las reivindicaciones 29 a 36 que comprende: (a) 70 - 90% p/p de polietilenglicol (PEG) con un peso molecular promedio dentro del rango de 2.000 a 10.000 Da; (b) 10 - 20% p/p de un sólido tal como manitol; (c) 0 - 2,0% p/p de lubricante; y (d) 0 - 2,0% p/p de saborizante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1018650.0A GB201018650D0 (en) | 2010-11-04 | 2010-11-04 | Methods and compositions |
US41212810P | 2010-11-10 | 2010-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083770A1 true AR083770A1 (es) | 2013-03-20 |
Family
ID=43414365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104129A AR083770A1 (es) | 2010-11-04 | 2011-11-04 | Metodos y composiciones, kit |
Country Status (22)
Country | Link |
---|---|
US (2) | US20130216493A1 (es) |
EP (1) | EP2635289B1 (es) |
JP (1) | JP5917537B2 (es) |
KR (1) | KR20130109171A (es) |
CN (1) | CN103313719A (es) |
AR (1) | AR083770A1 (es) |
AU (1) | AU2011324996B2 (es) |
BE (1) | BE1019494A3 (es) |
BR (1) | BR112013011012A2 (es) |
CA (1) | CA2816839A1 (es) |
EA (1) | EA201300540A1 (es) |
ES (1) | ES2401269B1 (es) |
GB (1) | GB201018650D0 (es) |
MX (1) | MX349690B (es) |
MY (1) | MY163067A (es) |
NL (1) | NL2007715C2 (es) |
NZ (1) | NZ611145A (es) |
SG (1) | SG189533A1 (es) |
TW (1) | TWI606832B (es) |
UA (1) | UA107998C2 (es) |
WO (1) | WO2012059725A1 (es) |
ZA (1) | ZA201304052B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI535461B (zh) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法 |
KR20170098980A (ko) | 2012-09-11 | 2017-08-30 | 노어긴 비.브이. | Peg 및 아스코르베이트를 포함하는 조성물 |
TW201431556A (zh) * | 2012-10-26 | 2014-08-16 | Univ Northshore Healthsystem | 用於頭部和頸部鱗狀細胞癌之療法的包含聚乙二醇之組成物 |
CN103083733A (zh) * | 2013-02-19 | 2013-05-08 | 华熙福瑞达生物医药有限公司 | 一种医用体腔器械导入水性润滑剂 |
EP3934663A1 (en) * | 2019-03-05 | 2022-01-12 | Dow Global Technologies LLC | Polyethyleneglycol derivatives for inducing caspase activity |
CN113507933B (zh) * | 2019-03-05 | 2024-05-10 | 陶氏环球技术有限责任公司 | 诱导胱天蛋白酶活性 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2784897B1 (fr) * | 1998-10-27 | 2002-11-29 | Agronomique Inst Nat Rech | Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux |
AU2006244112B2 (en) * | 2005-05-06 | 2011-02-17 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
US8457025B2 (en) * | 2009-08-28 | 2013-06-04 | Telefonaktiebolaget L M Ericsson (Publ) | Method and network node for selecting a network prefix to be advertised in a communication network |
-
2010
- 2010-11-04 GB GBGB1018650.0A patent/GB201018650D0/en not_active Ceased
-
2011
- 2011-04-11 UA UAA201307040A patent/UA107998C2/uk unknown
- 2011-11-04 TW TW100140231A patent/TWI606832B/zh not_active IP Right Cessation
- 2011-11-04 AU AU2011324996A patent/AU2011324996B2/en not_active Ceased
- 2011-11-04 NZ NZ611145A patent/NZ611145A/en not_active IP Right Cessation
- 2011-11-04 SG SG2013032008A patent/SG189533A1/en unknown
- 2011-11-04 JP JP2013537197A patent/JP5917537B2/ja active Active
- 2011-11-04 EA EA201300540A patent/EA201300540A1/ru unknown
- 2011-11-04 AR ARP110104129A patent/AR083770A1/es unknown
- 2011-11-04 NL NL2007715A patent/NL2007715C2/en active
- 2011-11-04 ES ES201131772A patent/ES2401269B1/es active Active
- 2011-11-04 EP EP11785050.3A patent/EP2635289B1/en active Active
- 2011-11-04 CA CA2816839A patent/CA2816839A1/en not_active Abandoned
- 2011-11-04 BR BR112013011012A patent/BR112013011012A2/pt not_active IP Right Cessation
- 2011-11-04 WO PCT/GB2011/001561 patent/WO2012059725A1/en active Application Filing
- 2011-11-04 MY MYPI2013001602A patent/MY163067A/en unknown
- 2011-11-04 KR KR1020137013977A patent/KR20130109171A/ko not_active Application Discontinuation
- 2011-11-04 CN CN201180064013XA patent/CN103313719A/zh active Pending
- 2011-11-04 US US13/883,262 patent/US20130216493A1/en not_active Abandoned
- 2011-11-04 MX MX2013004963A patent/MX349690B/es active IP Right Grant
- 2011-11-04 BE BE2011/0645A patent/BE1019494A3/fr active
-
2013
- 2013-06-03 ZA ZA2013/04052A patent/ZA201304052B/en unknown
-
2016
- 2016-04-21 US US15/134,410 patent/US20160228467A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2816839A1 (en) | 2012-05-10 |
AU2011324996A1 (en) | 2013-05-02 |
US20160228467A1 (en) | 2016-08-11 |
SG189533A1 (en) | 2013-05-31 |
MX349690B (es) | 2017-08-09 |
TWI606832B (zh) | 2017-12-01 |
US20130216493A1 (en) | 2013-08-22 |
ZA201304052B (en) | 2014-02-26 |
JP5917537B2 (ja) | 2016-05-18 |
MX2013004963A (es) | 2013-08-27 |
BE1019494A3 (fr) | 2012-07-03 |
KR20130109171A (ko) | 2013-10-07 |
GB201018650D0 (en) | 2010-12-22 |
NZ611145A (en) | 2015-07-31 |
MY163067A (en) | 2017-08-15 |
ES2401269B1 (es) | 2014-02-19 |
CN103313719A (zh) | 2013-09-18 |
UA107998C2 (uk) | 2015-03-10 |
JP2013544809A (ja) | 2013-12-19 |
EA201300540A1 (ru) | 2013-09-30 |
WO2012059725A8 (en) | 2013-05-30 |
EP2635289B1 (en) | 2020-03-11 |
WO2012059725A1 (en) | 2012-05-10 |
BR112013011012A2 (pt) | 2016-08-23 |
EP2635289A1 (en) | 2013-09-11 |
NL2007715A (en) | 2012-05-07 |
TW201304785A (zh) | 2013-02-01 |
NL2007715C2 (en) | 2012-10-16 |
ES2401269A1 (es) | 2013-04-18 |
AU2011324996B2 (en) | 2015-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083770A1 (es) | Metodos y composiciones, kit | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
CR20150199A (es) | Análogos de 2´-cloro nucleósido para infección por vhc | |
PH12014502603A1 (en) | D-amino acid compounds for liver disease | |
MY162146A (en) | Pharmaceutical composition | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
ECSP14016014A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca | |
EA201492011A1 (ru) | Безводные фармацевтические составы для местного применения | |
CL2016000150A1 (es) | Compuestos y composiciones como inhibidores de la mek | |
MX2013003282A (es) | Materiales y metodos para mejorar la funcion gastrointestinal. | |
BR112015015870A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
AR080295A1 (es) | Composiciones para el cuidado bucal y metodos de tratamiento | |
BR112012019997A2 (pt) | composições de cuidado oral | |
EA201370006A1 (ru) | Местная фармацевтическая композиция, содержащая флурбипрофен | |
BR112016021034A8 (pt) | composição farmacêutica, uso da mesma e kit | |
TN2015000394A1 (en) | Pharmaceutical compositions comprising everolimus | |
NZ702357A (en) | 5,6-benzoflavone compositions for treating and/or preventing skin disease associated with hyperseborrhea | |
BR112013010884A2 (pt) | formulações compreendendo polietileno glicol | |
WO2014081702A3 (en) | Synthetic linear apelin mimetics for the treatment of heart failure | |
MX2018007871A (es) | Composiciones para el cuidado personal. | |
PE20142325A1 (es) | Composiciones derivadas de la quitosana | |
BR112021020941A2 (pt) | Composição farmacêutica parenteral isotônica, método para melhoria da estabilidade química da dita composição e uso de manitol | |
BR112015022196A2 (pt) | composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |